Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A6+L9 live probiotic
- Development stage
- Unknown
- Lead developer
- China Agricultural University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Buccal
01
Overview
A6+L9 live probiotic is an experimental combination of two specific probiotic bacterial strains, *Lactobacillus plantarum* A6 and *Lactobacillus casei* L9, developed by researchers at China Agricultural University. This live biotherapeutic product is formulated as a milk tablet intended for the prevention and treatment of chronic periodontitis. The therapeutic rationale is based on the ability of these specific strains to modulate the oral microbiome, inhibit the growth of periodontal pathogens such as *Porphyromonas gingivalis*, and attenuate local inflammatory responses in the gingival tissues. In clinical study settings, it is evaluated as an adjunct to standard initial periodontal therapy, such as scaling and root planing (SRP), to improve clinical parameters like probing depth and attachment level.
- Other names
- Lactobacillus plantarum A6 + Lactobacillus casei L9Lactobacillus plantarum A6 and Lactobacillus casei L9 live probiotic
Beyond the preview
Go deeper on A6+L9 live probiotic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A6+L9 live probiotic.